Phase II study of MTOR-inhibitor RAD001 and erlotinib for advanced, gemcitabine-refractory pancreatic cancer

被引：0
|
作者：
Javle, M. [1 ]
Fogelman, D. [1 ]
Kaseb, A. [1 ]
Varadhachary, G. [1 ]
Wolff, R. [1 ]
Abbruzzese, J. [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72262-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：104 / 104
页数：1
相关论文
共 50 条
  • [31] Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
    Kim, Yoon Jae
    Bang, Seungmin
    Park, Jeong Youp
    Park, Seung Woo
    Chung, Jae Bock
    Song, Si Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (03) : 529 - 533
  • [32] Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
    Yoon Jae Kim
    Seungmin Bang
    Jeong Youp Park
    Seung Woo Park
    Jae Bock Chung
    Si Young Song
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 529 - 533
  • [33] EFFECTS OF MTOR INHIBITOR EVEROLIMUS (RAD001) ON BLADDER CANCER CELLS
    Chiong, Edmund
    Lee, I-Ling
    Dadbin, Ali
    Sabichi, Anita L.
    McConkey, David J.
    Grossman, H. Barton
    JOURNAL OF UROLOGY, 2009, 181 (04): : 406 - 406
  • [34] Capecitabine is an effective treatment in gemcitabine-refractory advanced pancreatic cancer
    Arrazubi, V
    Illarramendi, J.
    Lainez, N.
    Salgado, E.
    Martinez, M.
    Amillano, K.
    Vera, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 75 - 75
  • [35] JASPAC 02: A phase II study of gemcitabine and oxaliplatin (GEMOX) for gemcitabine-refractory advanced biliary tract cancer
    Ohno, I.
    Fukutomi, A.
    Furuse, J.
    Okusaka, T.
    Asayama, M.
    Nakamori, S.
    Ishii, H.
    Okuno, T.
    Yamanaka, T.
    Boku, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S631 - S632
  • [36] The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer:: Results of a phase I study with pharmacokinetics
    Awada, Ahmad
    Cardoso, Fatima
    Fontaine, Christel
    Dirix, Luc
    De Greve, Jacques
    Sotiriou, Christos
    Steinseifer, Jutta
    Wouters, Carine
    Tanaka, Chiaki
    Zoellner, Ulrike
    Tang, Pui
    Piccart, Martine
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 84 - 91
  • [37] A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results
    Vannucchi, Alessandro M.
    Guglielmelli, Paola
    Lupo, Letizia
    Finazzi, Maria Chiara
    Tozzi, Lorenzo
    Biamonte, Flavia
    Masciulli, Arianna
    Susini, Maria Chiara
    Pancrazzi, Alessandro
    Finazzi, Guido
    Paratore, Simona
    Marchioli, Roberto
    Bosi, Alberto
    Barbui, Tiziano
    Rambaldi, Alessandro
    Barosi, Giovanni
    BLOOD, 2010, 116 (21) : 143 - 143
  • [38] Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Witzig, Thomas E.
    Gertz, Morie
    LaPlant, Betsy
    Hayman, Suzanne
    Camoriano, John
    Lacy, Martha
    Bergsagel, P. Leif
    Chuma, Stacey
    DeAngelo, Daniel
    Treon, Steven P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (03) : 237 - 242
  • [39] Clinical Activity of Azacitidine In Combination with the Oral mTOR Inhibitor Everolimus (RAD001) In Relapsed and Refractory AML: Interim Analysis of a Phase Ib/II Study
    Wei, Andrew H.
    Sadawarte, Sonali
    Catalano, John
    Schwarer, Anthony P.
    Avery, Sharon
    Patil, Sushrut S.
    Spencer, Andrew
    BLOOD, 2010, 116 (21) : 1352 - 1353
  • [40] A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors.
    Tabernero, J
    Rojo, F
    Burris, H
    Casado, E
    Macarulla, T
    Jones, S
    Dimitrijevic, S
    Hazell, K
    Shand, N
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 193S - 193S
12345